Easy Health (02661) December 15 to December 18 The stock offering is expected to be listed on December 23

According to the Zhitong Finance App, Easy Health (02661) will offer shares from December 15 to December 18, 2025. The company plans to sell 26.54 million shares globally, of which Hong Kong sales account for 10%, international sales account for 90%, and 15% over-allotment rights, at a price of HK$22.68 per share. Each lot is 200 shares, and it is expected that the shares will be traded on the Stock Exchange on December 23, 2025.

The company provides health-related and insurance-related solutions. According to the Sullivan Report, the company ranked 10th in the Chinese digital comprehensive health service and health insurance service market in terms of revenue in 2024. The company is committed to providing protection and support to those in need through a set of health solutions that are easy to use, accurate, and affordable.

The company provides health-related services to users seeking comprehensive health solutions, including promotion and consultation related to early disease screening, health examination and consultation, medical appointment services, and sales of health products. As an important part of the company's services, the company also empowers industry participants to plan high-quality popular science content in the form of digital marketing and promote health-related public initiatives. In order to fund users' health expenses and meet their insurance needs, the company also provides users with easy access to various health insurance products through insurance-related services on the company's Internet insurance platform. The company's comprehensive platform provides health services and insurance funding resources, which can meet the overall health needs of users.

The Group entered into a cornerstone investment agreement with Aoqin Heming Investment Partnership (Limited Partnership) (“Aoqin Heming”) in the Guangdong Hengqin Guangdong-Macao Deep Cooperation Zone. According to this, Aoqin Heming has agreed to abide by certain conditions to subscribe or facilitate its designated entities to subscribe for the relevant number of shares that can be purchased for a total of approximately RMB 100 million according to the sale price. Based on the sale price of HK$22.68 per share, the total number of shares to be subscribed by Aoqin Heming is 4.8018 million shares.

Based on the offer price of HK$2,268 per share offered (assuming that the over-allotment rights are not exercised), the net proceeds from the global offering would be approximately HK$513.4 million. The Group plans to use the net proceeds from the global sale for the following purposes: approximately 40.0% will be used to enhance the Group's brand awareness, increase user participation and strengthen cooperation with business partners; approximately 20.0% will be used for medical research and real-world research; approximately 20.0% will be used to enhance the Group's technical capabilities in the field of AI and big data to be more widely used in the Group's products and services; approximately 10.0% will be used to expand into more regions and overseas markets; and approximately 10.0% for working capital and other general corporate purposes.